Published in Oncotarget on November 01, 2010
No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget (2011) 1.68
Inhibition and eradication of human glioma with tumor-targeting Salmonella typhimurium in an orthotopic nude-mouse model. Cell Cycle (2012) 1.44
High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells. Oncotarget (2012) 1.34
Targeting adaptive glioblastoma: an overview of proliferation and invasion. Neuro Oncol (2014) 1.24
Fenofibrate-induced nuclear translocation of FoxO3A triggers Bim-mediated apoptosis in glioblastoma cells in vitro. Cell Cycle (2012) 1.23
Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. Oncotarget (2012) 1.22
The ketogenic diet for the treatment of malignant glioma. J Lipid Res (2014) 1.03
Chaetocin-induced ROS-mediated apoptosis involves ATM-YAP1 axis and JNK-dependent inhibition of glucose metabolism. Cell Death Dis (2014) 1.01
Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2. Curr Opin Oncol (2012) 1.00
Tumor metabolism of malignant gliomas. Cancers (Basel) (2013) 1.00
Glyceraldehyde-3-phosphate dehydrogenase: a promising target for molecular therapy in hepatocellular carcinoma. Oncotarget (2012) 0.95
Pyruvate kinase is a dosage-dependent regulator of cellular amino acid homeostasis. Oncotarget (2012) 0.90
FOXP3, a novel glioblastoma oncosuppressor, affects proliferation and migration. Oncotarget (2012) 0.90
Function of carbonic anhydrase IX in glioblastoma multiforme. Neuro Oncol (2012) 0.89
HIF-1 and c-Src mediate increased glucose uptake induced by endothelin-1 and connexin43 in astrocytes. PLoS One (2012) 0.88
Pyruvate kinase M2 expression, but not pyruvate kinase activity, is up-regulated in a grade-specific manner in human glioma. PLoS One (2013) 0.88
ATM-NFκB axis-driven TIGAR regulates sensitivity of glioma cells to radiomimetics in the presence of TNFα. Cell Death Dis (2013) 0.87
Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. J Neurooncol (2015) 0.86
Recent discoveries in the cycling, growing and aging of the p53 field. Aging (Albany NY) (2012) 0.85
Multivoxel ¹H MR spectroscopy is superior to contrast-enhanced MRI for response assessment after anti-angiogenic treatment of orthotopic human glioma xenografts and provides handles for metabolic targeting. Neuro Oncol (2013) 0.85
Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes. Oncotarget (2012) 0.83
Clinical aggressiveness of malignant gliomas is linked to augmented metabolism of amino acids. J Neurooncol (2016) 0.83
Phospho-ΔNp63α/SREBF1 protein interactions: bridging cell metabolism and cisplatin chemoresistance. Cell Cycle (2012) 0.83
Glucose-6-phosphatase is a key metabolic regulator of glioblastoma invasion. Mol Cancer Res (2014) 0.82
Inhibition of Fatty Acid Synthase Decreases Expression of Stemness Markers in Glioma Stem Cells. PLoS One (2016) 0.82
Recent progress in targeting cancer. Aging (Albany NY) (2011) 0.80
Capturing the molecular and biological diversity of high-grade astrocytoma in genetically engineered mouse models. Oncotarget (2012) 0.80
PERK silence inhibits glioma cell growth under low glucose stress by blockage of p-AKT and subsequent HK2's mitochondria translocation. Sci Rep (2015) 0.80
Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma. Oncotarget (2015) 0.78
Volumetric spiral chemical shift imaging of hyperpolarized [2-(13) c]pyruvate in a rat c6 glioma model. Magn Reson Med (2015) 0.78
Birth of MTH1 as a therapeutic target for glioblastoma: MTH1 is indispensable for gliomatumorigenesis. Am J Transl Res (2016) 0.77
Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma. Oncotarget (2016) 0.77
Hypoxia-mediated upregulation of MCT1 expression supports the glycolytic phenotype of glioblastomas. Oncotarget (2016) 0.77
Lactate dehydrogenase-A inhibition induces human glioblastoma multiforme stem cell differentiation and death. Sci Rep (2015) 0.77
Metabolic remodeling precedes mitochondrial outer membrane permeabilization in human glioma xenograft cells. Int J Oncol (2011) 0.76
WWOX modulates the gene expression profile in the T98G glioblastoma cell line rendering its phenotype less malignant. Oncol Rep (2014) 0.75
Cellular density effect on RGD ligand internalization in glioblastoma for MRI application. PLoS One (2013) 0.75
In search of druggable targets for GBM amino acid metabolism. BMC Cancer (2017) 0.75
Exploring the differences in metabolic behavior of astrocyte and glioblastoma: a flux balance analysis approach. Syst Synth Biol (2015) 0.75
Reconstructed Metabolic Network Models Predict Flux-Level Metabolic Reprogramming in Glioblastoma. Front Neurosci (2016) 0.75
The energy blockers bromopyruvate and lonidamine lead GL15 glioblastoma cells to death by different p53-dependent routes. Sci Rep (2015) 0.75
Evaluation of mitochondrial respiratory function in highly glycolytic glioma cells reveals low ADP phosphorylation in relation to oxidative capacity. J Neurooncol (2017) 0.75
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17
Wnt/beta-catenin signaling in development and disease. Cell (2006) 30.09
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science (1997) 24.61
Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science (1997) 22.80
Wnt signalling in stem cells and cancer. Nature (2005) 19.26
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell (2009) 18.31
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer (2008) 18.08
Tumour stem cells and drug resistance. Nat Rev Cancer (2005) 15.21
Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell (2007) 14.87
Hedgehog signaling in animal development: paradigms and principles. Genes Dev (2001) 14.75
The canonical Notch signaling pathway: unfolding the activation mechanism. Cell (2009) 14.72
Identification and characterization of the familial adenomatous polyposis coli gene. Cell (1991) 14.46
The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell (2002) 13.92
Wnt signaling: a common theme in animal development. Genes Dev (1997) 12.94
A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature (2003) 12.81
Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature (2003) 12.54
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst (2008) 11.93
Identification of FAP locus genes from chromosome 5q21. Science (1991) 11.41
Cancer stem cells. N Engl J Med (2006) 9.63
Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol (2009) 9.43
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature (2009) 9.15
Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer (2005) 9.04
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med (2009) 8.55
A paracrine requirement for hedgehog signalling in cancer. Nature (2008) 8.16
Secreted antagonists of the Wnt signalling pathway. J Cell Sci (2003) 8.02
A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling. Dev Cell (2003) 7.93
Aspirin use and reduced risk of fatal colon cancer. N Engl J Med (1991) 7.85
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol (2010) 7.73
Coexistence of quiescent and active adult stem cells in mammals. Science (2010) 7.54
LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature (2001) 7.44
Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature (1998) 7.43
Stem cells: units of development, units of regeneration, and units in evolution. Cell (2000) 7.36
Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell (2009) 7.09
LDL-receptor-related proteins in Wnt signal transduction. Nature (2000) 6.94
Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82
Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol (2009) 6.66
Medulloblastoma growth inhibition by hedgehog pathway blockade. Science (2002) 6.53
An LDL-receptor-related protein mediates Wnt signalling in mice. Nature (2000) 6.34
Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem (2006) 6.32
The many ways of Wnt in cancer. Curr Opin Genet Dev (2007) 6.29
LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development (2004) 6.21
Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature (2003) 6.07
Hedgehog: functions and mechanisms. Genes Dev (2008) 5.69
Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature (2002) 5.61
Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. Science (2007) 5.45
Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov (2006) 5.29
AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet (2000) 5.26
Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res (2006) 5.21
Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol (2007) 5.21
Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell (2004) 4.98
Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst (2002) 4.97
Monounsaturated fatty acid modification of Wnt protein: its role in Wnt secretion. Dev Cell (2006) 4.89
Casein kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction. Nature (2005) 4.88
Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature (2008) 4.60
Wnt genes. Cell (1992) 4.55
Notch signaling: the core pathway and its posttranslational regulation. Dev Cell (2009) 4.49
Lgr6 marks stem cells in the hair follicle that generate all cell lineages of the skin. Science (2010) 4.45
Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol (2001) 4.38
The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science (2010) 4.37
Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology (1994) 4.27
Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture. Cell Stem Cell (2010) 4.25
GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev (2009) 4.21
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A (2007) 4.15
Wnt signaling: is the party in the nucleus? Genes Dev (2006) 4.10
Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One (2008) 3.97
A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci U S A (2004) 3.95
Wnt/beta-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol (2008) 3.87
The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless. Cell (1987) 3.78
Beta-catenin hits chromatin: regulation of Wnt target gene activation. Nat Rev Mol Cell Biol (2009) 3.67
ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res (2005) 3.52
DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell (2009) 3.48
beta-catenin destruction complex: insights and questions from a structural perspective. Oncogene (2006) 3.43
NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells (2010) 3.42
Beta-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. Nat Struct Mol Biol (2005) 3.41
Direct evidence for a role of beta-catenin/LEF-1 signaling pathway in induction of EMT. Cell Biol Int (2002) 3.40
Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet (2000) 3.33
An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell (2004) 3.30
Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development (2007) 3.28
A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature (1999) 3.22
The head inducer Cerberus is a multifunctional antagonist of Nodal, BMP and Wnt signals. Nature (1999) 3.19
Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ (2006) 3.12
Wnt signaling: complexity at the surface. J Cell Sci (2006) 3.11
Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res (2007) 3.07
Notch promotes radioresistance of glioma stem cells. Stem Cells (2010) 3.07
The multifaceted role of Notch in cancer. Curr Opin Genet Dev (2006) 3.07
Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell (2008) 3.01
Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst (2007) 2.75
Dual and opposing roles of primary cilia in medulloblastoma development. Nat Med (2009) 2.73
Insights into Wnt binding and signalling from the structures of two Frizzled cysteine-rich domains. Nature (2001) 2.67
Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res (2010) 2.67
Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci U S A (2010) 2.66
Skinny hedgehog, an acyltransferase required for palmitoylation and activity of the hedgehog signal. Science (2001) 2.58
Beta-catenin is required for endothelial-mesenchymal transformation during heart cushion development in the mouse. J Cell Biol (2004) 2.57
Alternative wnt signaling is initiated by distinct receptors. Sci Signal (2008) 2.52
Targeting Hedgehog--a cancer stem cell pathway. Clin Cancer Res (2010) 2.50
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol (2008) 7.30
Radial glia cells are candidate stem cells of ependymoma. Cancer Cell (2005) 5.21
Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (2012) 5.09
Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell (2011) 3.11
Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer (2004) 3.05
Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med (2011) 2.93
The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell (2013) 2.74
Fiber density index correlates with reduced fractional anisotropy in white matter of patients with glioblastoma. AJNR Am J Neuroradiol (2005) 1.90
Cancer stem cells are enriched in the side population cells in a mouse model of glioma. Cancer Res (2008) 1.75
Beta-catenin regulates wound size and mediates the effect of TGF-beta in cutaneous healing. FASEB J (2006) 1.47
Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene (2002) 1.45
High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Res (2006) 1.42
Peripheral nerve tumors: management strategies and molecular insights. J Neurooncol (2004) 1.35
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol (2013) 1.35
High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. Clin Cancer Res (2008) 1.34
Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J Clin Invest (2011) 1.27
Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol (2002) 1.26
MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1. Cancer Sci (2010) 1.23
Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. Cancer Res (2003) 1.20
Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Clin Cancer Res (2011) 1.20
Extracellular vesicles--vehicles that spread cancer genes. Bioessays (2012) 1.19
Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Res (2008) 1.19
GATA6 is an astrocytoma tumor suppressor gene identified by gene trapping of mouse glioma model. Proc Natl Acad Sci U S A (2007) 1.15
Pathological and molecular progression of astrocytomas in a GFAP:12 V-Ha-Ras mouse astrocytoma model. Am J Pathol (2005) 1.15
A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. J Exp Med (2011) 1.13
Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System. Clinical article. J Neurosurg (2009) 1.12
Three-dimensional in vivo modeling of vestibular schwannomas and surrounding cranial nerves with diffusion imaging tractography. Neurosurgery (2011) 1.10
Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression. Cancer Res (2009) 1.10
Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development. Cancer Res (2010) 1.07
Gene expression profiling reveals unique molecular subtypes of Neurofibromatosis Type I-associated and sporadic malignant peripheral nerve sheath tumors. Brain Pathol (2004) 1.06
Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res (2007) 1.06
Orthopaedic manifestations of neurofibromatosis in children: an update. Clin Orthop Relat Res (2002) 1.05
Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature. Neuro Oncol (2007) 1.04
Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. Oncogene (2004) 1.02
Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. Genome Res (2012) 1.02
The spectrum of somatic and germline NF1 mutations in NF1 patients with spinal neurofibromas. Neurogenetics (2009) 1.02
A human transferrin-vascular endothelial growth factor (hnTf-VEGF) fusion protein containing an integrated binding site for (111)In for imaging tumor angiogenesis. J Nucl Med (2005) 1.01
Targeting the Tie2/Tek receptor in astrocytomas. Am J Pathol (2004) 1.01
A proximity ligation assay using transiently transfected, epitope-tagged proteins: application for in situ detection of dimerized receptor tyrosine kinases. Biotechniques (2010) 1.00
Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme. Neurobiol Dis (2011) 0.99
Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings. J Cancer Res Clin Oncol (2010) 0.96
High-resolution longitudinal screening with magnetic resonance imaging in a murine brain cancer model. Neoplasia (2004) 0.96
Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. Neuro Oncol (2014) 0.96
Mouse models to interrogate the implications of the differentiation status in the ontogeny of gliomas. Oncotarget (2011) 0.95
Surgical management of cervical spine manifestations of neurofibromatosis Type 1: long-term clinical and radiological follow-up in 22 cases. J Neurosurg Spine (2011) 0.94
Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate). Cancer Res (2009) 0.94
Malignant peripheral nerve sheath tumors. Neurosurg Clin N Am (2004) 0.94
Conditional astroglial Rictor overexpression induces malignant glioma in mice. PLoS One (2012) 0.93
Identification and selected reaction monitoring (SRM) quantification of endocytosis factors associated with Numb. Mol Cell Proteomics (2012) 0.91
Molecular regulators of angiogenesis in the developing nervous system and adult brain tumors (review). Int J Oncol (2003) 0.90
In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy. Mol Cancer Res (2012) 0.89
Loss of collapsin response mediator Protein1, as detected by iTRAQ analysis, promotes invasion of human gliomas expressing mutant EGFRvIII. Cancer Res (2009) 0.89
Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1. Neurosurgery (2009) 0.89
Genome-wide high-resolution analysis of DNA copy number alterations in NF1-associated malignant peripheral nerve sheath tumors using 32K BAC array. Genes Chromosomes Cancer (2009) 0.88
Expression of GATA6 in the human and mouse central nervous system. Brain Res Dev Brain Res (2005) 0.88
Neoangiogenesis in human astrocytomas: expression and functional role of angiopoietins and their cognate receptors. Front Biosci (2003) 0.88
Malignant and benign ganglioglioma: a pathological and molecular study. Neuro Oncol (2007) 0.87
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. Acta Neuropathol (2014) 0.87
Regulation of the pathological vasculature of malignant astrocytomas by angiopoietin-1. Neoplasia (2005) 0.87
Role of Ang1 and its interaction with VEGF-A in astrocytomas. J Neuropathol Exp Neurol (2004) 0.86
Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft. Int J Cancer (2010) 0.86
Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis. Hum Mutat (2012) 0.85
Comparison of aprotinin and tranexamic acid in adult scoliosis correction surgery. Eur Spine J (2012) 0.85
Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice. Nucl Med Biol (2011) 0.85
Monoarticular pseudogout of the hip presenting as septic arthritis: a case report. Acta Orthop Traumatol Turc (2011) 0.85
Differential transformation capacity of neuro-glial progenitors during development. Proc Natl Acad Sci U S A (2013) 0.85
Mouse glioma gene expression profiling identifies novel human glioma-associated genes. Ann Neurol (2002) 0.85
Phosphatidylinositol 3'-kinase and MAPK/ERK kinase 1/2 differentially regulate expression of vascular endothelial growth factor in human malignant astrocytoma cells. Neuro Oncol (2002) 0.85
Information gaps for patients requiring craniotomy for benign brain lesion: a qualitative study. J Neurooncol (2009) 0.85
AIRP best cases in radiologic-pathologic correlation: Spinal conus dermoid cyst with lipid dissemination. Radiographics (2012) 0.85
Epigenetic regulation of glial fibrillary acidic protein by DNA methylation in human malignant gliomas. Neuro Oncol (2010) 0.85
Angiogenesis in nervous system disorders. Neurosurgery (2003) 0.85
Role of the Rap1 GTPase in astrocyte growth regulation. Glia (2003) 0.84
A novel neurofibromin (NF1) interaction with the leucine-rich pentatricopeptide repeat motif-containing protein links neurofibromatosis type 1 and the French Canadian variant of Leigh's syndrome in a common molecular complex. J Neurosci Res (2013) 0.84
The role of drebrin in glioma migration and invasion. Exp Cell Res (2012) 0.83
Vestibular Schwannomas presenting with haemorrhage: clinical presentation and histopathological evaluation of an unusual entity. Br J Neurosurg (2009) 0.83
Role of angiopoietin-2 in regulating growth and vascularity of astrocytomas. J Oncol (2010) 0.83
Fractionated stereotactic radiotherapy for acoustic neuroma: single-institution experience at The Princess Margaret Hospital. Cancer (2007) 0.82
Multiphoton ANS fluorescence microscopy as an in vivo sensor for protein misfolding stress. Cell Stress Chaperones (2011) 0.81
Role of moesin in hyaluronan induced cell migration in glioblastoma multiforme. Mol Cancer (2013) 0.81
Tumors of the central nervous system: clinical aspects, molecular mechanisms, unanswered questions, and future research directions. J Child Neurol (2008) 0.81
Aberrant G protein signaling in nervous system tumors. J Neurosurg (2002) 0.81
Radiation induced peripheral nerve tumors: case series and review of the literature. J Neurooncol (2007) 0.80
Canonical TGF-β pathway activity is a predictor of SHH-driven medulloblastoma survival and delineates putative precursors in cerebellar development. Brain Pathol (2012) 0.80
The need to protect the thyroid gland during image intensifier use in orthopaedic procedures. Acta Orthop Belg (2004) 0.80
A novel high-resolution in vivo imaging technique to study the dynamic response of intracranial structures to tumor growth and therapeutics. J Vis Exp (2013) 0.80
Intermittent atlantoaxial subluxation caused by a prolapsing neurofibroma. Case report. J Neurosurg Spine (2008) 0.79
Intracranial halo pin penetration causing brain injury secondary to poor halo care technique: a case report and literature review. Cases J (2008) 0.79
Telomerase activity is a biomarker for high grade malignant peripheral nerve sheath tumors in neurofibromatosis type 1 individuals. Genes Chromosomes Cancer (2008) 0.79
Proteomics: present and future implications in neuro-oncology. Neurosurgery (2008) 0.79
Loss of p53 cooperates with K-ras activation to induce glioma formation in a region-independent manner. Glia (2013) 0.78
Rap1 activity is elevated in malignant astrocytomas independent of tuberous sclerosis complex-2 gene expression. Int J Oncol (2003) 0.78
Mice with GFAP-targeted loss of neurofibromin demonstrate increased axonal MET expression with aging. Glia (2007) 0.78